Sanofi-Aventis | Jevtana (Medication)


Jevtana/cabazitaxel is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

Jevtana 25 mg/m2 administered every three weeks as a one-hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout. ...

Side Effect:

Serious side effects of Jevtana include low white blood cell counts that could lead to serious or life-threatening infections, severe allergic reactions, gastrointestinal symptoms (nausea, severe vomiting and diarrhea) that could lead to death, and kidney failure.

Common side effects of Jevtana include:low white blood cell count; low red blood cell count (anemia). Symptoms of anemia include shortness of breath and tiredness; low blood platelet count; tiredness; nausea; vomiting; diarrhea; constipation; weakness.

Blood in the urine; back pain; decreased appetite; fever; shortness of breath; stomach (abdominal) pain; change in your sense of taste; cough; joint pain; hair loss; numbness, tingling, burning or decreased sensation in your hands or feet. ...


Before receiving Jevtana, tell your doctor if you:had allergic reactions in the past; have kidney or liver problems. Jevtana should not be given to patients with liver problems (hepatic impairment); are age 65 or older as these patients (may be more likely to experience certain adverse reactions, including low white blood cell count with or without fever, tiredness, weakness, fever, dizziness, urinary tract infection and dehydration); have any other medical conditions.

If you are female and are pregnant or plan to become pregnant bear in mind that Jevtana can harm your unborn baby, are breastfeeding or plan to breastfeed. Consult your doctor. ...